HOLY NAME UNIVERSITY

COLLEGE OF HEALTH SCIENCES

DEPARTMENT OF NURSING
City of Tagbilaran

DRUG STUDY

Name of Patient: ____________________________ Address: ________________________________________Impression: _________________________________________

Date Admitted: ___________________________ Ward: _______________________ Room: ________________ Status: ______________ Age: _________ Sex: ___________

Date Generic Brand DOSAG Route & CLASSIFICATION: INDICATION CONTRA NURSING EVALUATION
Ordered Name E Frequency MECHANISM OF ACTION
Name INDICATION RESPONSIBILITIES
Biaxin Clarithro 500/tab 1 tab OD Inhibits protein synthesis at Treatment  - BEFORE:
mycin the level of the 50S bacterial of the Documented
~ Assess patient for infection
ribosome. Lower respirat hypersensitivit
(vital signs; appearance
ory tract y
of wound, sputum, urine, and
infections  -
stool; WBC) at beginning
including Coadministrati
of therapy.
pneumonia on with
pimozide, ~ Obtain specimens
cisapride, for culture and sensitivity
ergotamine, before initiating therapy.
and
DURING:
dihydroergota
mine ~ Administer around the
 - clock, without regard to
History of meals. Food slows but does
cholestatic not decrease the extent
jaundice or of absorption.
hepatic
~ Instruct patient to take
 dysfunction medication around the clock
associated with and to finish the drug
previous use of completely as directed, even
clarithromycin if feeling better.
 -
AFTER:
Coadministrati
on with ~ Advise patient to report the
colchicine in signs of super infection
patients with (black, furry overgrowth on
kidney (renal) the tongue; vaginal itching
or liver or discharge; loose or foul-
(hepatic) smelling stools).
impairment
~ Instruct the patient to notify
 -
health care professional
Coadministrati
if symptoms do not improve
on with HMG-
within a few days
CoA reductase
inhibitors
(statins) that
are extensively
metabolized by
CYP3A4
(lovastatin, sim
vastatin), due
to the
increased risk
of muscle
disease
(myopathy),
including
destruction of
 muscle tissue
(rhabdomyolys
is)

Ipatropiu Duavent 1 every 8 Pharmacodynamics: Ipratrop -Management -Patients with -Check inhaler technique.
m neb ampoule hours ium bromide is an of reversible hypertrophic - Ensure that patients are able
Bromide inhalation anticholinergic bronchospasm obstructive to correctly use the delivery
+ bronchodilator that reduces associated w/ cardiomyopathy device for their medication and
or consider use of a space if
Salbuta the formation of cyclic obstructive
tachyarrhythmia appropriate.
mol guanosine monophosphate airway . - If administering by nebulisers
Sulfate (cGMP), a mediator of diseases eg-Patients with use a mouthpiece rather than
bronchospasm, thereby bronchial known face mask.
relaxing the smooth muscles asthma, hypersensitivity - If administered by nebuliser
of the bronchi and COPD. to any the dilution of the solution
bronchioles. It is a potent ingredient in should be adjusted according
-For use in the product or to equipment and length of
bronchodilator, particularly in
patients with to atropine and administration.
large bronchial airway; some
chronic its derivatives. - Paradoxical bronchospasm
evidence suggests that
obstructive has occurred with nebulised
Ipratropium bromide also has
pulmonary solution, therefore first dose
bronchodilator activity in
disease should be used under medical
small airways.
(COPD) on a supervision.
Pharmacokinetics: Pulmone regular inhaled - Caution should be taken not
b: Only a small amount of bronchodilator to confuse Atrovent with
Ipratropium reaches the who continue Alupent.
systemic circulation after to have - Evaluate therapeutic
response.
inhalation. Some Ipratropium evidence of
is inadvertently swallowed bronchospasm
but it is poorly absorbed from and who
the gastrointestinal tract. require a
 second
bronchodilator.
Calcuim Caltrate 1 tab OD Reduces total acid load in Gi Acid - -Record amount and
Carbonat Plus tract, elevates gastric pH to indigestion, consistency of tools
Contraindicated
e reduce pepsin activity, calcium -Monitor calcium level
in patients with
strengthens gastric mucosal supplement ventricular -WOF evidence of
barrier and increases hypercalcemia (NV,
fibrillation or
esophageal sphincter tone
hypercalcemiaheadache, confusion, and
anorexia)
NEURO 1 cap OD A coenzyme that stimulate Used for Vit. B Hypersensitivi Determine reticulocyte count,
BION metabolic function and is complex ty to any of hct, Vit.B12, iron, folate
(Vitamin needed for cell replication, deficiencies; the active levels before beginning
B- hematopoiesis, and neuritis, ingredients or therapy.
complex) nucleoprotein and myelin polyneuritis, excipients of -Obtain a sensitivity test
synthesis. diabetic
Neurobion history before administration
neuritis,
neuralgia, -Avoid I.V. administration
lumbalgia, because faster systemic
sciatica, elimination will reduce
intercostal effectiveness of vitamin.
&trigeminal
neuralgia, peri -don’t give large doses
pheral routinely because drug is lost
neuroparalysis, through excretion.
arthralgia & -Protect Vit.B 12 from light.
myalgia. Don’t refrigerate or freeze.

Lyrica Pregabali 1 tab TID Binds with high affinity to Treatment of Hypersensitivit -obtain patient history before
n thealpha2-delta site (an neuropathic y to the active medication.
auxiliary subunit of voltage- pain in adults. substance or to
 gated calcium channels) in As adjunctive any of the -monitor hypersensitivity of
CNS tissues. therapy of excipients. patient to drug and other
partial seizures Lactation component.
with or without
-monitor for decreased
secondarily
platelet count.
generalization
in patient aged -monitor for elevated creatine
12 and above. kinase

Acetadot ACETY 1 sachet TID PO: Decreases the build up PO: Antidote In patients

e LCYSTE of of a hepatotoxic metabolite in for the with a prior
-Monitor signs of
INE Acetylcys acetaminophen overdosage.  management history of
angioedema, including
teine of potentially hypersensitivit rashes, raised patches of red
IV: Decreases the build-up of
(Fluimuci hepatotoxic y to any of the or white skin (welts),
a hepatotoxic metabolite in
l) 100 mg overdosage of ingredients. burning/itching skin, swelling
acetaminophen overdosage. 
acetaminophen Also, in in the face, and difficulty
Inhaln: Degrades mucus, (should be asthmatics and breathing. Notify physician of
allowing easier mobilization administered patients with these signs immediately.
and expectoration.  within 24 hr of history of -Monitor other signs of
ingestion). IV:  bronchospasm. allergic reactions and
TherapeuticEffects: Antidote for anaphylaxis, especially after
PO: Prevention or lessening the IV administration. Signs
of liver damage following management include pulmonary symptoms
acetaminophen overdose.  (tightness in the throat and
of potentially
chest, wheezing, cough,
Inhaln: Lowers the viscosity hepatotoxic dyspnea) and skin reactions
of mucus overdosage of (rash, pruritus, urticaria).
acetaminophen Notify physician or nursing
(should be staff immediately if these
administered reactions occur.
within 8–10 hr -Monitor signs of
 of bronchospasm and respiratory
ingestion). Inh irritation, including
aln: Mucolytic wheezing, cough, dyspnea,
in the increased secretions, and
management tightness in the chest and
of conditions throat. Report excessive or
prolonged respiratory
associated with
problems to the physician.
thick viscid
-When used as a mucolytic,
mucous assess the quantity and
secretions. Unl consistency of sputum to help
abeled document whether this drug
Use: Preventio is successful in reducing the
n of viscosity of respiratory
radiocontrast- secretions.
induced renal -When implementing airway
dysfunction clearance techniques, attempt
(oral). to intervene when the drug
has produced maximum
mucolytic effects. Peak
responses typically occur 5–
10 min after inhalation.

Celecoxi Celebrex 500 mg BID PO -Inhibits the enzyme COX-2. -Relief of signs - -Assess range of motion,
b This enzyme is required for and symptoms Hypersensitivit degree of swelling, and pain
the synthesis of of y; in affected joints before and
prostaglandins. osteoarthritis, periodically throughout
-Cross-
rheumatoid therapy.
-Has analgesic, anti- sensitivity may
arthritis,
inflammatory, and antipyretic exist with -Assess patient for allergy to
ankylosing
properties. other NSAIDs, sulfonamides, aspirin, or
spondylitis,
including NSAIDs. Patients with these
and juvenile
rheumatoid aspirin; allergies should not receive
arthritis. celecoxib.
-History of
-Management allergic-type -Assess patient for skin rash
of acute pain reactions to frequently during therapy.
including sulfonamides; Discontinue at first sign of
primary rash; may be life-threatening.
dysmenorrhea. -History of
Stevens-Johnson syndrome
asthma,
may develop. Treat
urticaria, or
symptomatically; may recur
allergic-type
once treatment is stopped.
reactions to
aspirin or other
NSAIDs,
including the
aspirin triad
(asthma, nasal
polyps, and
severe
hypersensitivit
y reactions to
aspirin);
-Advanced
renal disease;
-Severe
hepatic
dysfunction;